U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class
Concept
Record UNII
70FBL3TX3E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
D-3263
Code English
3-(2-AMINOETHYL)-1-((1R,2S,5R)-2-ISOPROPYL-5-METHYL-CYCLOHEXANECARBONYL)-5-METHOXY-BENZIMIDAZOL-2-ONE
Systematic Name English
D 3263 [WHO-DD]
Common Name English
2H-BENZIMIDAZOL-2-ONE, 3-(2-AMINOETHYL)-1,3-DIHYDRO-5-METHOXY-1-(((1R,2S,5R)-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXYL)CARBONYL)-
Systematic Name English
D-3263 (FREE BASE)
Code English
Code System Code Type Description
PUBCHEM
44137358
Created by admin on Fri Jun 25 22:51:39 UTC 2021 , Edited by admin on Fri Jun 25 22:51:39 UTC 2021
PRIMARY
CLINICAL_TRIALS.GOV
D-3263 (FREE BASE)
Created by admin on Fri Jun 25 22:51:39 UTC 2021 , Edited by admin on Fri Jun 25 22:51:39 UTC 2021
PRIMARY Official Title: A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid TumorsPurpose: This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors.
CAS
947257-66-1
Created by admin on Fri Jun 25 22:51:39 UTC 2021 , Edited by admin on Fri Jun 25 22:51:39 UTC 2021
PRIMARY
FDA UNII
70FBL3TX3E
Created by admin on Fri Jun 25 22:51:39 UTC 2021 , Edited by admin on Fri Jun 25 22:51:39 UTC 2021
PRIMARY
This is a non-substance concept
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
Originator: Dendreon Corporation; Class: Antineoplastic, Small molecule; Mechanism of Action: Apoptosis stimulant, TRPM8 protein stimulant; Highest Development Phases: Suspended for Benign prostatic hyperplasia, Solid tumours; Most Recent Events: 31 Dec 2013 Suspended - Phase-I for Solid tumours in USA (PO), 31 Dec 2013 Suspended - Preclinical for Benign prostatic hyperplasia in USA (PO), 01 Dec 2011 Dendreon completes its phase I trial for Solid tumours in USA (NCT00839631)
This is a non-substance concept